By Fineline Cube Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification indicating the commencement of follow-up volume-based procurement (VBP) for national VBP drugs with expired procurement cycles in the alliance region. Participating regions alongside Shanghai include Beijing, Tianjin, Zhejiang, Anhui, Fujian, Jiangxi, Shandong, Hubei, Hunan, Chongqing, Sichuan, Yunnan, Tibet, and Gansu.
Involvement of 49 Drug Varieties in the Procurement
A total of 49 drug varieties are involved in this procurement initiative, including ambroxol, domperidone, and febuxostat. The prices of these drugs must align with the highest valid quotes, not exceed 1.8 times the price of any other lower-priced competitor, and must not be higher than the average winning price of products that have won national tender spots. This approach ensures a fair and competitive pricing mechanism for the drugs involved.
Selection Process and Procurement Cycle
Each alliance region selects the winning drugs based on the comprehensive score of the “Comprehensive Evaluation Indicator System.” The procurement cycle for each variety in different regions starts from the date of winning results implementation and ends on December 31, 2025. The procurement agreement is signed annually during the procurement cycle, providing a structured framework for the procurement process.-Fineline Info & Tech